tbuckley/cabot-search huggingface dataset:
Brote hídrico en turistas españoles que visitaron República Dominicana en Agosto 2002
Authors: A Paez Jimenez, R Pimentel, M V Martinez de Aragon, G Hernández Pezzi, S Mateo, J. F. Martinez Navarro
Journal: Eurosurveillance (2004)

El 3 de septiembre de 2002, el Servicio de Epidemiologia de Asturias informa al Centro Nacional de Epidemiologia (CNE, Espana) de la existencia de un numero elevado de casos de gastroenteristis en turistas que habian viajado a un hotel de Punta Cana (Republica Dominicana) en distintas fechas de agosto. En las muestras de heces de algunos casos que buscaron atencion sanitaria en el citado pais Dominicana se habian visualizado quistes de Entamoeba hystolityca.
El CNE comunica la existencia del posible brote a las Autoridades Sanitarias de Republica Dominicana y a los servicios de epidemiologia de las siete Comunidades Autonomas espanolas de donde provenian los casos, de manera que, se inicia una investigacion coordinada del mismo.
Inicialmente, se identificaron 76 casos espanoles. La duracion media de la enfermedad se estimo en 5.1+2.9 dias y el periodo de exposicion en 3.6+2.2 dias.
Mediante un estudio de cohorte, se establecio una tasa de ataque del 32.4%. Asumiendo un mismo nivel de exposicion de toda la cohorte, 216 (95% CI=114.75-317.25) turistas espanoles presentaron sintomas.
No se identifico E. hystolityca en ninguna de las muestras de heces provenientes de los casos que presentaban sintomatologia a su regreso a Espana y no habian recibido tratamiento.
El 10 de septiembre de 2002 se realizo una investigacion medioambiental en el hotel. Las muestras de hielo y diversos alimentos servidos en esa fecha en el buffet presentaban coliformes.
El consumo de agua proveniente de la red de abastecimiento del hotel fue el unico factor de riesgo asociado con la presencia de sintomas (RR= 3.55; 95% CI =1.13-10.99). 
Para evitar brotes similares en el futuro, es imprescindible garantizar la calidad del agua de consumo y el nivel minimo de formacion de los manipuladores de alimentos en este tipo de establecimientos.
Could payer mix affect length of stay or readmissions among an outpatient palliative care cohort?
Authors: Ali John Zarrabi, Karen Armstrong, Kimberly A. Curseen, Tammie E. Quest
Journal: Journal of Clinical Oncology (2017)

165 Background: Outpatient palliative care clinics (PCC) are a developing frontier of palliative medicine. Characterizing and promoting financially viable models for payment of services are imperative to the sustainability of PCC. There is a paucity of research addressing payer mix – meaning the breakdown of individuals and organizations that pay for a provider's services – in PCC or its impact on metrics important to quality in PC such as hospital length of stay (LOS) and hospital readmissions. We seek to describe the payer mix for our academic outpatient PC practice. Furthermore, we sought to identify if payer mix (commercial, government—Medicare, Medicaid – or self-pay) influenced hospital LOS, discharge to hospice, or readmissions. Methods: After obtaining IRB approval, we conducted a retrospective chart review of supportive oncology patients from 2014-2017 (n = 3137) using data restricted to ICD10 codes for solid tumors. We performed bivariate tests and multivariable logistic regressions to examine the main effects of length of stay (LOS), readmissions, insurance status, and discharge disposition using SAS version 9.4 (Cary, NC). Results: Payer mix included 711 (24%) commercial insurance enrollees, 2357 (75%) Medicare or Medicaid recipients, and 38 (1%) self-pay. Mean LOS was 12.7 days (SD 16.38). The majority (94%) of patients had more than 5 readmissions. Commercial insurance was associated with prolonged LOS ( &gt; = 30 days), discharge disposition to hospice, and hospital readmissions ( &gt; 5) compared to government insurance (p &lt; 0.05). Of the 3137 patients, 325 (10%) expired, 1328 (42%) were discharged to hospice, while 1463 (47%) were discharged to rehab, skilled nursing facilities or home care. Conclusions: The majority of patients in our academic PCC had governmental insurance and were less likely than those with commercial insurance to have prolonged LOS, discharge to hospice, or hospital readmission. These findings provide evidence that further investigation is needed to examine the effect of payer mix on PCC and patient outcomes.
US healthcare company fires 69 employees for refusing flu vaccination
Authors: Owen Dyer
Journal: BMJ (2017)

Essentia Health, which operates 15 hospitals and 75 clinics in Minnesota, Wisconsin, North Dakota, and Idaho, has fired 69 members of staff who refused to have the flu vaccine.

Hundreds of other Essentia workers received their flu shots last week after being warned that they would lose their jobs if they failed to meet a 20 November deadline to either be vaccinated or file an exemption request form. The company employs about 14 000 people.

Some of the fired employees had sought medical or religious exemptions, but these were strictly limited to documented evidence of vaccine allergy or of Guillain-Barre syndrome after previous vaccination. …
ST Elevations in the Setting of Hyperkalemia
Authors: Mark Heckle, Manyoo Agarwal, Shadwan Alsafwah
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Sorveglianza per patogeni respiratori e sindromi influenzali nei presidi medici - Paesi Bassi, inverno 1997-98
Authors: M. L.A. Heijnen, J W Dorigo-Zetsma, A I M Bartelds, B Wilbrink, M. J.W Sprenger
Journal: Eurosurveillance (1999)

E' dal 1970 che il Netherlands Institute of Primary Health Care (NIVEL) coordina le attivita di una rete sentinella di sorveglianza con 43 presidi medici. Questi presidi seguono l'1% della popolazione olandese, un campione rappresentativo della popolazione nazionale per quanto riguarda eta, sesso e livello di urbanizzazione (1). NIVEL utilizza i dati forniti dalla rete per calcolare, una volta alla settimana, l'incidenza di sindromi influenzali durante la stagione invernale. Dietro richiesta del NIVEL, dall'inverno del1992-3, l'Istituto Nazionale per la Salute Pubblica e l'Ambiente (Rijksinstituut voor Volksgezondheid en Milieu - RIVM) ha migliorato il sistema, includendo l'isolamento dei virus e l'esame dei tamponi nasali e della gola ottenuti da pazienti con infezioni acute delle vie respiratorie superiori (acute upper respiratory tract infections - ARI), di cui mediamente il 62% e costituito da sindromi influenzali. Il presente articolo riporta i principali risultati della sorveglianza delle sindromi influenzali e altre ARI notificate dai presidi medici olandesi nell'inverno 1997-98, determina l'associazione tra isolamento del virus influenzale e la notifica di sindromi influenzali e confronta gli isolati virali con la PCR (analisi con reazione a catena della polimerasi) effettuata su virus respiratori sinciziali (RSV), rhinovirus e enterovirus.
Five-year forward view: lessons from emergency care at the extremes of age
Authors: JS Minhas, D Minhas, T Coats, J Banerjee, D Roland
Journal: Journal of the Royal Society of Medicine (2017)

Objective The progressive rise in demand on NHS emergency care resources is partly attributable to increases in attendances of children and older people. A quality gap exists in the care provision for the old and the young. The Five Year Forward View suggested new models of care but that the “answer is not one-size-fits-all”. This article discusses the urgent need for person-centred outcome measures to bridge the gap that exists between demand and provision. Design This review is based on evidence gathered from literature searching across several platforms using a variety of search terms to account for the obvious heterogeneity, drawing on key ‘think-tank' evidence. Settings Qualitative and quantitative studies examining approaches to caring for individuals at the extremes of age. Participants Individuals at the extremes of age (infants and older people). Main Outcome Measures Understanding similarities and disparities in the care of individuals at the extremes of age in an emergency and non-emergency context. Results There exists several similarities and disparities in the care of individuals at the extremes of age. The increasing burden of health disease on the economy must acknowledge the challenges that exist in managing patients in emergency settings at the extremes of age and build systems to acknowledge the traits these individuals exhibit. Conclusion Commissioners of services must optimise the models of care delivery by appreciating the similarities and differences between care requirements in these two large groups seeking emergency care.
Low molecular weight heparin (LMWH) usage for cancer patients under palliative care.
Authors: Ahmed Ali, Amani Zayir, Adel Hamody, Shakeel Ahmed
Journal: Journal of Clinical Oncology (2017)

1 Background: Cancer patients are at increased risk of thromboembolic complications. Studies show that prophylactic low molecular weight heparin (LMWH) can successfully reduce incidence of venous thromboembolic events; however, a survival benefit for patients with advanced cancer who receive LMWH in a palliative setting has not been confirmed. Methods: We evaluated the survival of cancer patients undergoing palliative treatment in a tertiary care hospital in Saudi Arabia during 2016. Patients were followed from the day of palliative care initiation until the day of death, and we compared the survival of patients who received LMWH (enoxaparin) with those who did not. Gender, diagnosis (site of cancer), and date of diagnosis were considered for subgroup analysis. Results: Of the 209 patients included in this study, enoxaparin was administered to 91(about 44%), while 117 (about 56%) did not receive any LMWH, and the treatment of one patient was not clearly defined. Male and female patients are equally distributed (104 and 105 patients, respectively). Cancer sites included breast, brain, gastrointestinal, genitourinary, lung, hematological malignancies, bone, and others. Although there was generally no statistical difference in survival time between treated and untreated groups (approximately 48 days each), subgroup analyses showed a statistically significant but not clinically significant survival benefit for patients with genitourinary cancers, such as uterine, urinary bladder, ovarian, or prostatic carcinomas who received LMWH (14.15 to 63.85 Days, P=0.0046). Conclusions: Prophylactic treatment with LMWH provided no clinically significant survival benefit to terminally ill cancer patients when administered in conjunction with other medications. Further prospective trials are warranted. Clinical trial information: ONC0329.
P1.03-033 Analysis of T0 Lung-RADS Scores in UI Health's Minority-Based Lung Cancer Screening Program and Comparison to the NLST
Authors: Mary Pasquinelli, Kevin Kovitz, Juan Alban, Li Liu, Arkadiusz Dudek, Robert Winn, Karriem Watson, Martha Menchaca, Matthew Koshy, Arden Plumb, Lawrence Feldman
Journal: Journal of Thoracic Oncology (2017)
Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease
Authors: Subodh Verma, C. David Mazer, Mohammed Al-Omran, Silvio E. Inzucchi, David Fitchett, Uwe Hehnke, Jyothis T. George, Bernard Zinman
Journal: Circulation (2017)
Wide Complex Tachycardia in a Patient Without Conduction System Disease
Authors: Douglas J. Hall, Timothy W. Smith, Amit Noheria
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
In silico identification and biochemical characterization of novel substrates and inhibitors of NQO1
Authors: Karen A. Nolan, Richard Bryce, Ian J. Stratford
Journal: Cancer Research (2005)

3960   NQO1 is an obligate two-electron reductase that catalyses the reduction of a diverse range of substrates. It is a flavoprotein that exists as a homodimer and is biochemically characterised by its ability to use either NADH or NADPH as reducing cofactors and by its inhibition by the anticoagulant dicoumarol. NQO1 is constitutively expressed in a variety of tissues but over-expressed in many solid tumours as compared to surrounding normal tissue, thus making it a viable and attractive target for selective anticancer drug development. The primary aim of this study was to screen the NCI chemical database and the NCI cancer databases for their ability to bind in the active site of human NQO1. This allowed the following objectives to be achieved; firstly, potential candidates for lead optimisation as substrates or inhibitors were identified, and secondly the binding mode of these compounds was determined, in order to identify molecular features that could improve drug activity. This approach involved hierarchical computational screening of the NCI databases using the programs DOCK 4.0 and GOLD to predict protein-ligand binding mode and affinity. Using a stepwise  in silico  screening strategy compounds were subject to a minimised rigid docking screen and the top 1200 ligands with the highest binding energies were retained. A further computational screen was applied which allowed full ligand flexibility. The top 200 highest scoring compounds were further evaluated taking account of Lipinski parameters. Calculated binding energies for top-ranked ligands (-61 to -48 kcal/mol) were significantly higher than the substrate of the crystal structure, E09 (-39 kcal/mol). The docking studies suggest that NQO1 can accommodate ligands of different size and structure adopting a variety of binding modes and active site interactions. All ligands made at least one hydrogen bond contact with Tyr126 and Tyr128; these residues are recognised as being important in the catalytic mechanism of NQO1. Of the 50 top-ranked compounds from the NCI chemical database, 19 were available for biochemical and biological evaluation of their ability to act as substrates or inhibitors of NQO1. Most of these compounds act as competitive inhibitors of NQO1 with IC50 values in the range 0.4 to 7.5 micromolar. However, some quinone based structures act as substrates and these are undergoing further characterization.
Osimertinib in Untreated<i>EGFR</i>-Mutated Advanced Non–Small-Cell Lung Cancer
Authors: Jean-Charles Soria, Yuichiro Ohe, Johan Vansteenkiste, Thanyanan Reungwetwattana, Busyamas Chewaskulyong, Ki Hyeong Lee, Arunee Dechaphunkul, Fumio Imamura, Naoyuki Nogami, Takayasu Kurata, Isamu Okamoto, Caicun Zhou, Byoung Chul Cho, Ying Cheng, Eun Kyung Cho, Pei Jye Voon, David Planchard, Wu-Chou Su, Jhanelle E. Gray, Siow-Ming Lee, Rachel Hodge, Marcelo Marotti, Yuri Rukazenkov, Suresh S. Ramalingam
Journal: New England Journal of Medicine (2017)

Osimertinib is an oral, third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI–sensitizing and EGFR T790M resistance mutations. We compared osimertinib with standard EGFR-TKIs in patients with previously untreated, EGFR mutation–positive advanced non–small-cell lung cancer (NSCLC).
Stable Oxidative Cytosine Modifications Accumulate in Cardiac Mesenchymal Cells From Type2 Diabetes Patients
Authors: Francesco Spallotta, Chiara Cencioni, Sandra Atlante, Davide Garella, Mattia Cocco, Mattia Mori, Raffaella Mastrocola, Carsten Kuenne, Stefan Guenther, Simona Nanni, Valerio Azzimato, Sven Zukunft, Angela Kornberger, Duran Sürün, Frank Schnütgen, Harald von Melchner, Antonella Di Stilo, Manuela Aragno, Maarten Braspenning, Wim van Criekinge, Miles J. De Blasio, Rebecca H. Ritchie, Germana Zaccagnini, Fabio Martelli, Antonella Farsetti, Ingrid Fleming, Thomas Braun, Andres Beiras-Fernandez, Bruno Botta, Massimo Collino, Massimo Bertinaria, Andreas M. Zeiher, Carlo Gaetano
Journal: Circulation Research (2017)

Rationale: Human cardiac mesenchymal cells (CMSCs) are a therapeutically relevant primary cell population. Diabetes mellitus compromises CMSC function as consequence of metabolic alterations and incorporation of stable epigenetic changes. Objective: To investigate the role of α-ketoglutarate (αKG) in the epimetabolic control of DNA demethylation in CMSCs. Methods and Results: Quantitative global analysis, methylated and hydroxymethylated DNA sequencing, and gene-specific GC methylation detection revealed an accumulation of 5-methylcytosine, 5-hydroxymethylcytosine, and 5-formylcytosine in the genomic DNA of human CMSCs isolated from diabetic donors. Whole heart genomic DNA analysis revealed iterative oxidative cytosine modification accumulation in mice exposed to high-fat diet (HFD), injected with streptozotocin, or both in combination (streptozotocin/HFD). In this context, untargeted and targeted metabolomics indicated an intracellular reduction of αKG synthesis in diabetic CMSCs and in the whole heart of HFD mice. This observation was paralleled by a compromised TDG (thymine DNA glycosylase) and TET1 (ten–eleven translocation protein 1) association and function with TET1 relocating out of the nucleus. Molecular dynamics and mutational analyses showed that αKG binds TDG on Arg275 providing an enzymatic allosteric activation. As a consequence, the enzyme significantly increased its capacity to remove G/T nucleotide mismatches or 5-formylcytosine. Accordingly, an exogenous source of αKG restored the DNA demethylation cycle by promoting TDG function, TET1 nuclear localization, and TET/TDG association. TDG inactivation by CRISPR/Cas9 knockout or TET/TDG siRNA knockdown induced 5-formylcytosine accumulation, thus partially mimicking the diabetic epigenetic landscape in cells of nondiabetic origin. The novel compound (S)-2-[(2,6-dichlorobenzoyl)amino]succinic acid (AA6), identified as an inhibitor of αKG dehydrogenase, increased the αKG level in diabetic CMSCs and in the heart of HFD and streptozotocin mice eliciting, in HFD, DNA demethylation, glucose uptake, and insulin response. Conclusions: Restoring the epimetabolic control of DNA demethylation cycle promises beneficial effects on cells compromised by environmental metabolic changes.
Real world data on use of palbociclib in hormone-receptor (ER) positive HER2 negative metastatic breast cancer (MBC) among Asian patients
Authors: J. Chiu, R. Leung, H. Sze, P. Teo, P. Choi, T-C Lam, T. Yau, P. Cheng, F-Y Cheung, P. Cheung
Journal: Annals of Oncology (2017)
Evaluation of an NP-based model of palliative care delivery within an oncology clinic.
Authors: Sarah F. DAmbruoso, Neil Wenger, Anne Coscarelli, Sara A. Hurvitz, Christopher Pietras, Meghan Nechrebecki, Jennie Kung, Rena Desai Callahan, Jonathan Wade Goldman, Parvin F. Peddi, Drakaki Alexandra, Samuel A. Skootsky, Anne Margaret Walling
Journal: Journal of Clinical Oncology (2017)

163 Background: We initiated a nurse practitioner (NP)-based model of palliative care delivery embedded within an oncology clinic guided by a shared mental model (SMM) between palliative care, oncology, and psychosocial oncology clinicians in order to foster best practice collaboration and closed-loop communication between teams. These data represent processes and outcomes three years after initial implementation of the program. Methods: We evaluated program growth as well as advance care planning, hospice use, and utilization in patients with advanced cancer seen by the palliative care NP compared to patients receiving usual care from March 2014 to March 2017 at University-based oncology clinics. We developed a palliative care quality improvement tool integrating administrative and clinical data from multiple sources, including the electronic health record (EHR) and external hospices, using progressive methods of pulling data, such as natural language processing, in order to identify patients with advanced cancer and key process and end of life utilization measures. We used chi square tests to compare care received by the two groups. Results: There was good adoption of the intervention. The number of participating oncologists increased from 2 to 5 and the palliative care NP shifted from part-time to full-time after the first 1.5 years of implementation. Patients enrolled in the NP-based model of palliative care delivery were more likely to have a documented goals of care conversation (74.6% v. 9%, p &lt; 0.01), to be referred for additional psychosocial support (52.5% v. 30.9%, p &lt; 0.01), and to complete physician orders for life sustaining treatment (POLST) (20.3% v. 4.5%, p &lt; 0.01). There was no statistically significant difference in advance directive completion (28.8% v. 23.5%). Among decedents, patients enrolled in the NP-based model were more likely to be enrolled in hospice (50.5% v. 29.1%, p &lt; 0.01). There were non-statistically significant trends toward less hospital (4.6 days v. 5.6 days) and ICU use (1.0 day vs. 1.3 days) in the last 30 days of life. Conclusions: An NP-model of palliative care delivery within an oncology clinic led to important improvements in key palliative care processes and outcomes.
Informe sobre la primera cepa de PVL-SARM comunitaria en Latvia
Authors: E Miklaševics, S Hæggman, A Balode, B Sanchez, A Martinsons, B Olsson-Liljequist, U Dumpis
Journal: Eurosurveillance (2004)

En todo el mundo se han detectado infecciones por Staphylococcus aureus resistente a la meticilina adquiridas en la comunidad (CA-SARM). Este articulo presenta la caracterizacion del primer CA-SARM aislado en Latvia. Una cepa de PVL-SARM IV ST30 fue aislada de una muestra nasal y del cateter venoso central de un paciente con fiebre y fallo multiorganico. El perfil de electroforesis en campo pulsado de esta cepa era indistinguible del perfil de cepas MRSA SE00-3 aisladas en Suecia en 2002-2003 procedentes de 29 pacientes. Esta cepa esta ligada al area del Pacifico Sur y su emergencia en Suecia y en Latvia es una prueba de su diseminacion al nivel mundial.